MannKind (NASDAQ:MNKD) Upgraded to Buy at HC Wainwright

MannKind (NASDAQ:MNKD - Get Free Report) was upgraded by stock analysts at HC Wainwright to a "buy" rating in a research note issued on Wednesday, Marketbeat Ratings reports. The firm presently has a $9.00 price objective on the biopharmaceutical company's stock. HC Wainwright's target price points to a potential upside of 139.36% from the stock's current price. HC Wainwright also issued estimates for MannKind's Q2 2025 earnings at $0.05 EPS, Q3 2025 earnings at $0.05 EPS and Q4 2025 earnings at $0.05 EPS.

Other analysts have also recently issued reports about the company. Mizuho initiated coverage on MannKind in a report on Thursday, April 10th. They set an "outperform" rating and a $12.00 price objective for the company. Wall Street Zen cut MannKind from a "buy" rating to a "hold" rating in a report on Friday, June 27th. Seven analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, MannKind presently has a consensus rating of "Buy" and an average price target of $10.14.

MannKind Trading Down 3.6%

Shares of MannKind stock traded down $0.14 during trading on Wednesday, reaching $3.76. The company's stock had a trading volume of 2,310,832 shares, compared to its average volume of 2,432,801. The stock has a 50-day moving average price of $4.02 and a two-hundred day moving average price of $4.88. MannKind has a one year low of $3.51 and a one year high of $7.63. The stock has a market capitalization of $1.14 billion, a P/E ratio of 23.50 and a beta of 0.96.

MannKind (NASDAQ:MNKD - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported $0.04 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.03 by $0.01. The business had revenue of $78.35 million during the quarter, compared to analysts' expectations of $75.86 million. MannKind had a negative return on equity of 32.41% and a net margin of 10.12%. The firm's revenue for the quarter was up 18.1% compared to the same quarter last year. During the same period in the previous year, the business posted $0.05 earnings per share. As a group, sell-side analysts anticipate that MannKind will post 0.1 EPS for the current fiscal year.

Insider Activity at MannKind

In related news, Director Steven B. Binder sold 80,144 shares of the business's stock in a transaction that occurred on Tuesday, May 13th. The stock was sold at an average price of $4.69, for a total value of $375,875.36. Following the completion of the transaction, the director directly owned 1,006,611 shares in the company, valued at approximately $4,721,005.59. The trade was a 7.37% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP David Thomson sold 32,179 shares of the business's stock in a transaction that occurred on Tuesday, May 13th. The shares were sold at an average price of $4.68, for a total value of $150,597.72. Following the completion of the transaction, the executive vice president owned 772,427 shares of the company's stock, valued at $3,614,958.36. This represents a 4.00% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 266,198 shares of company stock valued at $1,143,244 over the last quarter. 2.70% of the stock is owned by insiders.

Hedge Funds Weigh In On MannKind

Several institutional investors and hedge funds have recently modified their holdings of the business. GF Fund Management CO. LTD. acquired a new position in MannKind during the 4th quarter worth approximately $37,000. Jones Financial Companies Lllp boosted its position in MannKind by 3,294.8% during the 4th quarter. Jones Financial Companies Lllp now owns 6,586 shares of the biopharmaceutical company's stock worth $42,000 after acquiring an additional 6,392 shares during the last quarter. Farther Finance Advisors LLC boosted its position in MannKind by 1,379.2% during the 2nd quarter. Farther Finance Advisors LLC now owns 7,396 shares of the biopharmaceutical company's stock worth $28,000 after acquiring an additional 6,896 shares during the last quarter. Kovitz Investment Group Partners LLC acquired a new position in MannKind during the 4th quarter worth approximately $65,000. Finally, Blueshift Asset Management LLC acquired a new position in MannKind during the 1st quarter worth approximately $51,000. 49.55% of the stock is currently owned by institutional investors and hedge funds.

MannKind Company Profile

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults.